STAAR Surgical Company (STAA)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-29
$24.54-2.77%
Close 2026-10-30 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-29
Research Workspace
Put STAA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 43% in its worst 12-month stretch.
View RiskSTAA’s China-led key-market growth is the central case, supported by exceptionally rapid recent revenue growth. Revenue grew 111% year over year in Q2 FY2026, and non-GAAP earnings beat consensus. STAA trades at 32× P/E versus a 30× peer median, below its 52× historical multiple. The price reflects less growth than our forecast, leaving room for the growth case. A 24% next-quarter miss probability and unsteady management threaten confidence in that case. Peer multiples imply a price about 6% below where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. STAA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering STAA (as of Oct 2026).
Based on 4 Wall Street analysts offering 12-month price targets for STAA in the last 4 months.
Continue this research
Compare STAA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| STAA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 7 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put STAA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Accelerate revenue growth in key markets
Upgrade highlights growth potential in key market, aligning with objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $24.54
The last 12 months of price, then the range of analyst 12-month targets from today’s $24.54.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Accelerate revenue growth in key markets
Positive outlook on China growth supports revenue growth objective.
Advances: Maintain disciplined capital allocation and cost management
Buyback supports disciplined capital allocation objective.
Share buyback indicates strong capital management.
Advances: Accelerate revenue growth in key markets
Profitability from China supports revenue growth objective.
Advances: Accelerate revenue growth in key markets
Q2 profit rebound supports revenue growth objective.
Advances: Accelerate revenue growth in key markets
Record revenue surge supports growth in key markets.
Advances: Maintain disciplined capital allocation and cost management
Cash position supports disciplined capital allocation strategy.
